Teva to report first quarter 2018 financial results on may 3, 2018
Jerusalem--(business wire)--teva pharmaceutical industries ltd. (nyse: teva) announced today that it will release its first quarter 2018 financial results on thursday, may 3, 2018 at 7:00 a.m. et. teva will host a conference call and live webcast on the same day, at 8:00 a.m. et to discuss its first quarter 2018 results and overall business environment. a question & answer session will follow this discussion. in order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): united states 1-866-254-0808 international 44 (0) 1452 541003for a list of other international toll-free numbers, click here. passcode: 9496209 a live webcast of the call will also be available on teva's website at: ir.tevapharm.com please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. following the conclusion of the call, a replay of the webcast will be available within 24 hours on the company's website. the replay can also be accessed until may 31, 2018, 9:00 a.m. et by calling united states 1-866-247-4222 or international 44(0)1452550000; passcode: 9496209. about teva teva pharmaceutical industries ltd. (nyse and tase: teva) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. headquartered in israel, teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. in specialty medicines, teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. teva's net revenues in 2017 were $22.4 billion. for more information, visit www.tevapharm.com. cautionary note regarding forward-looking statements this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995 regarding teva's innovative therapeutic solutions, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. important factors that could cause or contribute to such differences include risks relating to: commercial success of the various teva's innovative therapeutic solutions; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; our specialty medicines business, including: competition for our specialty products, especially copaxone®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our r&d programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the u.s. government of our fcpa investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our u.s. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets; compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex medicare and medicaid reporting and payment obligations; and environmental risks; other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and other factors discussed in our annual report on form 10-k for the year ended december 31, 2017, including in the section captioned “risk factors,” and in our other filings with the u.s. securities and exchange commission, which are available at www.sec.gov and www.tevapharm.com. forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. you are cautioned not to put undue reliance on these forward-looking statements. ##
